Zhai Y.F.,Xian Jiaotong University |
Wu H.-Q.,Xian Jiaotong University |
Lu D.,Changhai Hospital of Shanghai |
Wang H.-Q.,Xian Jiaotong University |
And 2 more authors.
Journal of Sichuan University (Medical Science Edition) | Year: 2012
Objective To study whether erythropoietin ( EPO) has the anti-aging effect and the mechanisms of how it effects. Methods 5% D-galactose hypodermic injection for 6 weeks to establish the aging model. Divided rats into 5 groups randomly: the normal control (group A) , the aging model (group B) , the low dosage [I 000 U/(kg · d)] of recombinant human erythropoietin (rhEPO) intervene (group C) , the middle dosage [3 000 U/( kg · d)] of rhEPO intervene (group D) and the high dosage [5 000 U/(kg · d)] of rhEPO intervene (group E ) , 10 rats in each group. Morris water maze was used to comparing the behavioral indexes. After decapitating the rats, the malonaldehyde (MDA), Na+-K+ ATPase, total antioxidant capacity (T-AOC) and superoxide dismutase (SOD) of brain tissue were tested, one rat from each group was selected randomly to observe the hippocampal ultramicrostructure. Results (1)Compared with group A, the learning and memory ability of group B reduced, the level of MDA, the Na+-K+ ATPase, T-AOC and the SOD activities of brain tissue decreased ( P<0 . 0 5 ) , besides, a series of aging changes were observed in the hippocampal ultramicro-structure in group B. (2) Compared with group B, an improved learning and memory ability of group D, a reduced MDA content and an increased activity of Na +-K+ ATPase, T-AOC and the SOD activities of brain tissue in group D were also observed with a improved hippocampal ultramicro-structure. (3) The low dosage of rhEPO intervention could against the decrease of the activities of brain Na+-K+ ATPase, SOD of aging rat (P<0 . 0 5 ) , but had no significant effects on the rest of the indicators, the high dosage of rhEPO intervention had no significant improvements on various indicators of aging rats in high dosage of rhEPO intervention groupwas noticed ( P > 0 . 05). Conclusion The middle dosage of EPO has the anti-aging effect, and its mechanisms may be related to enhancing the antioxidant enzymes activity and increasing the antioxidant capacity.
Li Y.,Changhai Hospital of Shanghai
Zhonghua fu chan ke za zhi | Year: 2012
To observe the selective regulation of peroxisome proliferator-activated receptors (PPAR) on fatty acid binding protein-4 (FABP4) in human syncytiotrophoblasts. Cultivate normal human syncytiotrophoblast cells, and put in the specific antagonists and agonists of PPAR each subtypes receptors, then observe the different expression of FABP4 mRNA and protein. Pretreated the human syncytiotrophoblast cells with the agonists (GW7647, GW0742) and antagonists (GW6471, GSK0660) of PPARα and PPARβ receptors, the expression of the FABP4 was not significantly change (P > 0.05). However pretreated with PPAR γ agonists (rosiglitazone, 1×10(-9), 1×10(-8), 1×10(-7) and 1×10(-6) mol/L), the expression of FABP4 mRNA and protein could be dose dependent-promoted significantly (mRNA: 1.27 ± 0.12, 1.45 ± 0.14, 1.57 ± 0.14, 1.72 ± 0.12, protein:1.10 ± 0.08, 1.37 ± 0.09, 1.60 ± 0.13, 1.79 ± 0.14; P < 0.05), furthermore, the promotion can be dose dependent-reversed by specific antagonists GW9662 (mRNA:0.92 ± 0.06, 0.77 ± 0.06, 0.64 ± 0.05, 0.55 ± 0.05, protein:0.91 ± 0.03, 0.78 ± 0.06, 0.70 ± 0.07, 0.55 ± 0.06; P < 0.05). In normal human syncytiotrophoblast cells, FABP4 is a target factor of PPARγ. PPARγ regulated the expression of FABP4 mRNA and protein selectively. And the regulation will not be influenced by the other two PPAR subtypes.
Liu B.F.,Changhai Hospital of Shanghai
Zhongguo gu shang = China journal of orthopaedics and traumatology | Year: 2011
To discuss diagnosis and treatment of iatrogenic purulent lumbar spinal infection. From December 2006 to January 2010, 4 patients with iatrogenic purulent lumbar spinal infection were treated with posterior debridement. There were 2 males and 2 females, ranging in age from 50 to 66 years (respectively in 52, 66, 58, 50 years); in course of disease from 2 weeks to 2.5 months (respectively in 21, 14, 60, 75 days ). All patients had fever, lumbago, local tenderness and limited lumbar activity before operation. White blood cell count (WBC), erythrocyte sedimentation rate (ESR) were abnormal. The clinical effects were evaluated by symptoms and laboratory examination. Symptoms of lumbago and fever vanished in 4 patients, of which wounds were primary healing without complications. The patients were followed up for 3 months, no infection (WBC, C-reactive protein and ESR were normal) and lumbar instability were found. Iatrogenic purulent lumbar spinal infection can be diagnosed according to course of disease, clinical symptoms and signs, imaging finding. In the items, magnetic resonance imaging finding have necessarily specificity, once finding abscess-formation, will promptly operate.
Xu S.,Shanghai University |
Xu Z.,Shanghai University |
Liu B.,Second Military Medical University |
Sun Q.,Shanghai University |
And 4 more authors.
Leukemia Research | Year: 2014
The distal cytoplasmic motifs of the leukemia inhibitory factor receptor α-chain (LIFRα-CT3) and its TAT fusion protein (TAT-CT3) can independently suppress cell viability and induce myeloid differentiation in human leukemia HL-60 cells in our previous studies. But its underlying mechanism remains undefined. Herein, we show that a prokaryotic expressed TAT-CT3 induced a rapid elevation of STAT3 phosphorylation (pSTAT3), and then suppress the transcription of miR-155 and induce the elevation of SOCS-1, which further inhibited STAT3 phosphorylation for a long-term period. Our result indicated a novel mechanism of TAT-CT3 to promote HL60 cells differentiation, which provides some potential therapeutic targets for future acute myelogenous leukemia therapy. © 2014 Elsevier Ltd.
Ke M.,Peking Union Medical College |
Zou D.,Changhai Hospital of Shanghai |
Yuan Y.,Shanghai Ruijin Hospital |
Li Y.,Capital Medical University |
And 4 more authors.
Neurogastroenterology and Motility | Year: 2012
Background The study evaluated efficacy and safety of the 2mg dose of prucalopride compared to placebo in patients with chronic constipation (CC) from the Asia-Pacific region. Methods Randomized, placebo-controlled, parallel-group, phase III study with 2-week run-in, 12-week treatment phase, and 1-week follow-up. Adult patients with CC (≤2 spontaneous bowel movements per week) received 2mg prucalopride or placebo, once-daily, for 12weeks. Primary efficacy measure was percentage of patients with average of ≥3 spontaneous complete bowel movements (SCBMs) per week (Responders) during the 12-week treatment. A key secondary endpoint was Responders during first 4weeks of treatment. Other efficacy assessments were based on patient diaries, their assessments of symptoms and quality of life, and investigator's assessment on efficacy of treatment. Safety assessments included adverse events, laboratory values, and cardiovascular events. Key Results Efficacy and safety were evaluated for 501 patients who received study drug. On the primary endpoint, prucalopride was significantly more effective than placebo with 83 (33.3%) vs 26 (10.3%) patients having a weekly average of ≥3 SCBMs during the 12-week treatment (P <0.001). Respective percentages were 34.5%vs 11.1% over first 4weeks (P <0.001). On other secondary endpoints, clinical improvement was generally larger and statistically superior (P <0.001) in the prucalopride group. Most frequently reported adverse events were diarrhea, nausea, abdominal pain, and headache. Conclusion & Inferences Prucalopride 2mg given once-daily significantly improved bowel function, associated symptoms, and satisfaction in CC over a 12-week treatment period, and was safe and well tolerated by patients in the Asia-Pacific region. © 2012 Blackwell Publishing Ltd.